Entering the medical insurance is not the only way, 15 anti-cancer drugs enter the commercial supplementary medical insurance

[industry trends of pharmaceutical network] on December 23, Foshan medical insurance bureau released the announcement of "Foshan social insurance fund administration on the implementation of Foshan commercial supplementary medical insurance" Ping An Buddhist medical insurance " It is worth noting that it has included some high-cost cancer self financing drugs that are not included in the national medical insurance catalog into the reimbursement scope, and most of them are new specialty drugs newly listed in China in recent two years There are 15 tumor drugs including three PD-1 drugs, odevo, coreda and tuoyi, Pfizer breast cancer new drug aiboxin, Xinji / Baiji Shenzhou lenalidomide, Novartis leukemia old drug, Gleevec, etc Entering medical insurance is not the only way (photo source: pharmaceutical network) It is understood that "Ping An Buddhist medical insurance" is under the guidance of Foshan municipal government, led by Foshan Medical Security Bureau and municipal social insurance fund management bureau, and underwritten by Foshan branch of Ping an Endowment Insurance Co., Ltd Adopt the way of voluntary insurance and implement the "three not two not one coverage" welfare, that is, do not exclude children, do not exclude the elderly, do not exclude the group of patients (including patients with major diseases); no waiting period, no medical insurance directory restrictions; the coverage covers the chronic diseases in the inpatient and outpatient, specific diseases in the outpatient and cancer drugs In fact, since the establishment of the National Health Insurance Bureau in 2018, in addition to constantly adjusting the medical insurance catalog and negotiating access to some high-priced new special drugs and drugs for rare diseases, it has also announced this year that it will stop and eliminate the local medical insurance supplement catalog Although these measures can save medical insurance funds, they also limit the flexibility of local medical insurance Some high priced drugs, especially cancer drugs, that can't enter the national catalog through national negotiation, have lost the channels that used to benefit patients through the local supplement catalog At this time, local commercial supplementary medical insurance has become another innovative form of medicine into medical insurance Cable   As early as November 21, 2018, Shenzhen Municipal Human Resources and social security bureau published the list of drugs for supplementary medical insurance for serious and serious diseases in 2018, including several heavy-duty anticancer drugs on the market in 2018: PD-1 antibody keytruda (malignant melanoma), ALK inhibitor aleutic Nil (ALK positive lung cancer), olapari (ovarian cancer), a PARP inhibitor, and piperacillin, a CDK4 / 6 inhibitor   In March 2019, in order to further improve the medical security system of Shenzhen, effectively improve the level of serious and extra serious diseases, and effectively reduce the burden of medical expenses for patients with major diseases, aleatinib hydrochloride capsule (ansanza), pabolizumab injection (coreda), olaparib tablet (lipzhuo) were added to the catalogue of supplementary medical insurance drugs for serious and extra serious diseases of Shenzhen Six varieties of lucotinib phosphate tablets (jiekewei), piperacillin capsules (aiboxin) and lanruitide acetate for injection (somadoulin) were used since July 1 Industry insiders said that for the high-priced tumor drugs that failed in the health insurance negotiation this year or missed the negotiation window, the local commercial supplementary medical insurance can be said to create a new path for drugs to reach the health insurance, and the probability that drug companies can enter the local directory through local innovation channels will gradually increase in the future Especially for innovative drugs, they have their own unique clinical value Even if they don't enter the medical insurance through negotiation, there are other channels to expand the market Commercial medical insurance is just one of the methods Within the available range, enterprises need to consider more solutions comprehensively.